AsianScientist (Apr. 29, 2014) – Biotechnology company Mucosis B.V. has entered into a long-term collaboration and license agreement with China-based Changchun BCHT Biotechnology Co (BCHT) and raised EUR5 million (US$6.9 million) in a new financing round.
Under the agreement with BCHT, Mucosis will receive an equity investment along with customary payments including royalties in return for a license to its SynGEM® prefusion F vaccine candidate for prevention of respiratory syncytial virus (RSV) and the Mimopath® platform for other disease targets. The license is valid within the People’s Republic of China on an exclusive basis and non-exclusively in certain other Asian countries.
“We believe that our Mimopath® platform combined with BCHT’s expertise in vaccine development creates a substantial opportunity in China and other parts of Asia to develop differentiated and medically relevant vaccines,” said Thomas Johnston, CEO of Mucosis. “We see this partnership as a further validation of our clinical-stage platform and its potential to combat infectious diseases.”
In addition to BCHT, the financing round was supported by Mucosis’s current investors, which include BioGeneration Ventures, MedSciences Capital, NV NOM (Investment and Development Agency for the Northern Netherlands) and Utrecht Holdings.
———
Source: Mucosis B.V.; Photo: Dawn Huczek/Flickr/CC.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
